First-quarter catalysts for the smaller players

After delving into the key clinical events due for big pharma and biotech companies, Evaluate Vantage now looks at smaller players − those with a market cap of under $2bn.

Among them, Rhythm and Supernus are gunning to expand their patient groups, while Wave Life Sciences will hope that the New Year does not start in the same way as 2020 did.